Pharmacological interventions for daytime sleepiness and sleep disorders in Parkinson's disease: Systematic review and meta-analysis

Parkinsonism and Related Disorders

Volumn 27, Issue , 2016, Pages 25-34

  Rodrigues, Tiago Martins ^a,b   Caldas, Ana Castro ^c   Ferreira, Joaquim J ^a,c  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

Daytime somnolence; Nocturnal sleep problems; Parkinson's disease; Pharmacological interventions; Systematic review

Indexed keywords

CAFFEINE; DOXEPIN; ESZOPICLONE; MELATONIN; MODAFINIL; PERGOLIDE; PLANT MEDICINAL PRODUCT; RIVASTIGMINE; UNCLASSIFIED DRUG; YANG XUE QING NAO; DOPAMINE RECEPTOR STIMULATING AGENT; WAKEFULNESS PROMOTING AGENT;

ARTICLE; ASTHENIA; CONSTIPATION; DAYTIME SOMNOLENCE; DISEASE DURATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; EPWORTH SLEEPINESS SCALE; EXCESSIVE DAYTIME SLEEPINESS; FATIGUE; FOLLOW UP; HUMAN; INSOMNIA; META ANALYSIS; MULTICENTER STUDY (TOPIC); NAUSEA; ORTHOSTATIC HYPOTENSION; PARASOMNIA; PARKINSON DISEASE; POLYSOMNOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEDATION; SIDE EFFECT; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; DISORDERS OF EXCESSIVE SOMNOLENCE; PROCEDURES; SLEEP WAKE DISORDERS;

DISORDERS OF EXCESSIVE SOMNOLENCE; DOPAMINE AGONISTS; HUMANS; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SLEEP WAKE DISORDERS; WAKEFULNESS-PROMOTING AGENTS;

EID: 84971504976     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2016.03.002     Document Type: Review

References (75)

1. R.L. Nussbaum, C.E. Ellis, Alzheimer's disease and Parkinson's disease, N. Engl. J. Med. 348 (14) (2003) 1356-1364.
2. D. Twelves, K.S.M. Perkins, C. Counsell, Systematic review of incidence studies of Parkinson's disease, Mov. Disord. 18 (1) (2003) 19-31.
3. S.K. Van Den Eeden, C.M. Tanner, A.L. Bernstein, R.D. Fross, A. Leimpeter, D.A. Bloch, L.M. Nelson, Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity, Am. J. Epidemiol. 157 (11) (2003) 1015-1022.
4. K.R. Chaudhuri, D.G. Healy, A.H. Schapira, Non-motor symptoms of Parkinson's disease: diagnosis and management, Lancet Neurol. 5 (3) (2006) 235-245.
5. K.R. Chaudhuri, A.H. Schapira, Non-motor symptoms of Parkinson's disease:dopaminergic pathophysiology and treatment, Lancet Neurol. 8 (5) (2009) 464-474.
6. D.B. Rye, The two faces of Eve: dopamine's modulation of wakefulness and sleep, Neurology 63 (8 Suppl 3) (2004) S2eS7.
7. P. Barone, A. Antonini, C. Colosimo, R. Marconi, L. Morgante, T.P. Avarello, E. Bottacchi, A. Cannas, G. Ceravolo, R. Ceravolo, G. Cicarelli, R.M. Gaglio, R.M. Giglia, F. Iemolo, M. Manfredi, G. Meco, A. Nicoletti, M. Pederzoli, A. Petrone, A. Pisani, F.E. Pontieri, R. Quatrale, S. Ramat, R. Scala, G. Volpe, S. Zappulla, A.R. Bentivoglio, F. Stocchi, G. Trianni, P.D. Dotto, PRIAMO study group, The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease, Mov. Disord. 24 (11) (2009) 1641-1649.
8. A.J. Lees, N.A. Blackburn, V.L. Campbell, The nighttime problems of Parkinson's disease, Clin. Neuropharmacol. 11 (6) (1988) 512-519.
9. J.J. Ferreira, K. Desboeuf, M. Galitzky, C. Thalamas, C. Brefel-Courbon, N. Fabre, J.M. Senard, J.L. Montastruc, C. Sampatio, O. Rascol, Sleep disruption, daytime somnolence and "sleep attacks" in Parkinson's disease: a clinical survey in PD patients and age-matched healthy volunteers, Eur. J. Neurol. 13 (3) (2006) 209-214.
10. R.D. Sweet, F.H. McDowell, Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients, Ann. Intern. Med. 83 (4) (1975) 456-463.
11. R.P. Lesser, S. Fahn, S.R. Snider, L.J. Cote, W.P. Isgreen, R.E. Barrett, Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy, Neurology 29 (9 Pt 1) (1979) 1253-1260.
12. P.A. Nausieda, W.J. Weiner, L.R. Kaplan, S. Weber, H.L. Klawans, Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis, Clin. Neuropharmacol. 5 (2) (1982) 183-194.
13. E. Tandberg, J.P. Larsen, K. Karlsen, A community-based study of sleep disorders in patients with Parkinson's disease, Mov. Disord. 13 (6) (1998) 895-899.
14. D.B. Rye, Excessive daytime sleepiness and unintended sleep in Parkinson's disease, Curr. Neurol. Neurosci. Rep. 6 (2) (2006) 169-176.
15. (NICE) TNI for CE. Parkinson's disease diagnosis and management in primary and secondary care. Clin. Guidel. 35. https://www.nice.org.uk/guidance/cg35.
16. T.A. Zesiewicz, K.L. Sullivan, I. Arnulf, K.R. Chaudhuri, J.C. Morgan, G.S. Gronseth, J. Miyasaki, D.J. Iverson, W.J. Weiner, Quality Subcommitee of the American Academy of Neurology, Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology, Neurology 274 (11) (2010) 924-931.
17. J. Higgins, S. Green (Eds.), Cochrane handbook for Systematic Reviews of Interventions, Version 5.1.0, Cochrane Collab, 2011 (September):265.
18. W.G. Ondo, R. Fayle, F. Atassi, J. Jankovic, Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial, J. Neurol. Neurosurg. Psychiatry 76 (12) (2005) 1636-1639.
19. C.H. Adler, J.N. Caviness, J.G. Hentz, M. Lind, J. Tiede, Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease, Mov. Disord. 18 (3) (2003) 287-293.
20. B. Hogl, M. Saletu, E. Brandauer, S. Glatzi, B. Frauscher, K. Seppi, H. Ulmer, G. Wenning, W. Poewe, Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebocontrolled polygraphic trial, Sleep 25 (8) (2002) 905-909.
21. R.B. Postuma, A.E. Lang, R.P. Munhoz, K. Charland, A. Pelletier, M. Moscovich, L. Filla, D. Zanatta, S. Rios Romenets, R. Altman, R. Chuang, B. Shah, Caffeine for treatment of Parkinson disease: a randomized controlled trial, Neurology 79 (7) (2012) 651-658.
22. C.L. Comella, M. Morrissey, K. Janko, Nocturnal activity with nighttime pergolide in Parkinson disease: a controlled study using actigraphy, Neurology 64 (8) (2005) 1450-1451.
23. G.A. Dowling, J. Mastick, E. Colling, J.H. Carter, C.M. Singer, M.J. Aminoff, Melatonin for sleep disturbances in Parkinson's disease, Sleep. Med. 6 (5) (2005) 459-466.
24. M. Menza, R.D. Dobkin, H. Marin, M. Gara, K. Bienfait, A. Dicke, C.L. Comella, C. Cantor, L. Hyer, Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo, Mov. Disord. 25 (11) (2010) 1708-1714.
25. S. Rios Romenets, L. Creti, C. Fichten, S. Bailes, E. Libman, A. Pelletier, R.B. Postuma, Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson's disease - a randomized study, Park. Relat. Disord. 19 (7) (2013) 670-675.
26. W. Pan, S. Kwak, G. Li, Y. Chen, D. Cai, Therapeutic effect of Yang-Xue-Qing-Nao granules on sleep dysfunction in Parkinson's disease, Chin. Med. 8 (2013) 14.
27. R. Di Giacopo, A. Fasano, D. Quaranta, G. Della Marca, F. Bove, A.R. Bentivoglio, Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease, Mov. Disord. 27 (4) (2012) 559-561.
28. M.W. Mahowald, Eyes wide shut. The dangers of sleepy driving, Minn. Med. 83 (8) (2000) 25-30.
29. J. Connor, G. Whitlock, R. Norton, R. Jackson, The role of driver sleepiness in car crashes: a systematic review of epidemiological studies, Accid. Anal. Prev. 33 (1) (2001) 31-41.
30. R. Broughton, Q. Ghanem, Y. Hishikawa, Y. Sugita, S. Nevsimalova, B. Roth, Life effects of narcolepsy in 180 patients from North America, Asia and Europe compared to matched controls, Can. J. Neurol. Sci. 8 (4) (1981) 299-304.
31. D. Leger, K. Scheuermaier, P. Philip, M. Paillard, C. Guilleminault, SF-36:evaluation of quality of life in severe and mild insomniacs compared with good sleepers, Psychosom. Med. 63 (1) (2001) 49-55.
32. G.K. Zammit, J. Weiner, N. Damato, G.P. Sillup, C.A. McMillan, Quality of life in people with insomnia, Sleep 22 (Suppl 2) (1999) S379eS385.
33. P.K. Pal, K. Thennarasu, J. Fleming, M. Schulzer, T. Brown, S.M. Calne, Nocturnal sleep disturbances and daytime dysfunction in patients with Parkinson's disease and in their caregivers, Park. Relat. Disord. 10 (3) (2004) 157-168.
34. M.C. Smith, H. Ellgring, W.H. Oertel, Sleep disturbances in Parkinson's disease patients and spouses, J. Am. Geriatr. Soc. 45 (2) (1997) 194-199.
35. J.K. Walsh, A.D. Krystal, D.A. Amato, R. Rubens, J. Caron, T.C. Wessel, K. Schaefer, J. Roach, G. Wallenstein, T. Roth, Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations, Sleep 30 (8) (2007) 959-968.
36. A.D. Krystal, Treating the health, quality of life, and functional impairments in insomnia, J. Clin. Sleep. Med. 3 (1) (2007) 63-72.
37. R. Pahwa, M.A. Stacy, S.A. Factor, K.E. Lyons, F. Stocchi, B.P. Hersh, L.W. Elmer, D.D. Truong, N.L. Earl, EASE-PD Adjunct Study Investigators, Ropinirole 24- hour prolonged release: randomized, controlled study in advanced Parkinson disease, Neurology 68 (14) (2007) 1108-1115.
38. C. Trenkwalder, B. Kies, M. Rudzinska, J. Fine, J. Nikl, K. Honczarenko, P. Dioszeghy, D. Hill, T. Anderson, V. Myllyla, J. Kassubek, M. Steiger, M. Zucconi, E. Tolosa, W. Poewe, E. Surmann, J. Whitesides, B. Boroojerdi, K.R. Chaudhuri, Recover Study Group, Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER), Mov. Disord. 26 (1) (2011) 90-99.
39. F. Stocchi, L. Barbato, G. Nordera, A. Berardelli, S. Ruggieri, Sleep disorders in Parkinson's disease, J. Neurol. 245 (Suppl 1) (1998) S15eS18.
40. E.C. Wolters, H.J. Tesselaar, International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson's disease, J. Neurol. 243 (3) (1996) 235-240.
41. UK Madopar CR Study Group, A comparison of Madopar CR and standard Madopar in the treatment of nocturnal and early-morning disability in Parkinson's disease. The U.K. Madopar CR Study Group, Clin. Neuropharmacol. 12 (6) (1989) 498-505.
42. L. Ghys, E. Surmann, J. Whitesides, B. Boroojerdi, Effect of rotigotine on sleep and quality of life in Parkinson's disease patients: post hoc analysis of RECOVER patients who were symptomatic at baseline, Expert Opin. Pharmacother. 12 (13) (2011) 1985-1998.
43. N. Giladi, A. Fichtner, W. Poewe, B. Boroojerdi, Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson's disease, J. Neural Transm. 117 (12) (2010) 1395-1399.
44. W.H. Poewe, O. Rascol, N. Quinn, E. Tolosa, W.H. Oertel, E. Martignoni, M. Rupp, B. Boroojerdi, SP 515 Investigators, Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial, Lancet Neurol. 6 (6) (2007) 513-520.
45. J.Y. Yun, H.J. Kim, J.Y. Lee, Y.E. Kim, J.S. Kim, J.M. Kim, B.S. Jeon, Comparison of once-daily versus twice-daily combination of ropinirole prolonged release in Parkinson's disease, BMC Neurol. 13 (2013) 113.
46. K. Ray Chaudhuri, P. Martinez-Martin, K.A. Rolfe, J. Cooper, C.B. Rockett, L. Giorgi, W.G. Ondo, Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson's disease, Eur. J. Neurol. 19 (1) (2012) 105-113.
47. I. Rektorova, M. Balaz, J. Svatova, K. Zarubova, I. Honig, V. Dostal, S. Sedlackova, I. Nestrasil, J. Mastik, M. Bares, J. Veliskova, L. Dusek, Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study, Clin. Neuropharmacol. 31 (5) (2008) 261-266.
48. K. Kieburtz, Parkinson Study Group PramiBID Investigators, Twice-daily, lowdose pramipexole in early Parkinson's disease: a randomized, placebocontrolled trial, Mov. Disord. 26 (1) (2011) 37-44.
49. G. Ebersbach, K. Hahn, M. Lorrain, A. Storch, Tolcapone improves sleep in patients with advanced Parkinson's disease (PD), Arch. Gerontol. Geriatr. 51 (3) (2010) e125ee128.
50. R.M. Trosch, J.H. Friedman, M.C. Lannon, R. Pahwa, D. Smith, L.C. Seeberger, C.F. O'Brien, P.A. LeWitt, W.C. Koller, Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience, Mov. Disord. 13 (3) (1998) 377-382.
51. J.M. Rabey, T. Prokhorov, A. Miniovitz, E. Dobronevsky, C. Klein, Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration, Mov. Disord. 22 (3) (2007) 313-318.
52. A. Iranzo, J. Santamaría, D.B. Rye, F. Valldeoriola, M.J. Martí, E. Muñoz, I. Vilaseca, E. Tolosa, Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD, Neurology 65 (2) (2005) 247-252.
53. J. Cummings, S. Isaacson, R. Mills, H. Williams, K. Chi-Burris, A. Corbett, R. Dhall, C. Ballard, Pimavanserin for patients with Parkinson's disease psychosis:a randomised, placebo-controlled phase 3 trial, Lancet 383 (9916) (2014) 533-540.
54. M. Menza, R.D. Dobkin, H. Marin, M.H. Mark, M. Gara, S. Buyske, K. Bienfait, A. Dicke, A controlled trial of antidepressants in patients with Parkinson disease and depression, Neurology 72 (10) (2009) 886-892.
55. D. Weintraub, S. Mavandadi, E. Mamikonyan, A.D. Siderowf, J.E. Duda, H.I. Hurtig, A. Colcher, S.S. Horn, S. Nazem, T.R. Ten Have, M.B. Stern, Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease, Neurology 75 (5) (2010) 448-455.
56. W.G. Ondo, L. Shinawi, A. Davidson, D. Lai, Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial, Park. Relat. Disord. 17 (3) (2011) 156-159.
57. K. Seppi, D. Weintraub, M. Coelho, S. Perez-Lloret, S.H. Fox, R. Katzenschlager, E.M. Hametner, W. Poewe, O. Rascol, C.G. Goetz, C. Sampaio, The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease, Mov. Disord. 26 (Suppl 3) (2011) S42eS80.
58. J.J. Ferreira, R. Katzenschlager, B.R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schupbach, E. Tolosa, C. Trenkwalder, A. Schapira, A. Berardelli, W.H. Oertel, Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease, Eur. J. Neurol. 20 (1) (2013) 5-15.
59. T.I. Morgenthaler, V.K. Kapur, T. Brown, T.J. Swick, C. Alessi, R.N. Aurora, B. Boehlecke, A.L. Chesson, L. Friedman, R. Maganti, J. Owens, J. Pancer, R. Zak, Standards of Practice Committee of the American Academy of Sleep Medicine, Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin, Sleep 30 (12) (2007) 1705-1711.
60. S. Schutte-Rodin, L. Broch, D. Buysse, C. Dorsey, M. Sateia, Clinical guideline for the evaluation and management of chronic insomnia in adults, J. Clin. Sleep. Med. 4 (5) (2008) 487-504.
61. R.N. Aurora, R.S. Zak, R.K. Maganti, S.H. Auerbach, K.R. Casey, S. Chowdhuri, A. Karippot, K. Ramar, D.A. Kristo, T.I. Morgenthaler, Best practice guide for the treatment of REM sleep behavior disorder (RBD), J. Clin. Sleep. Med. 6 (1) (2010) 85-95.
62. R.N. Aurora, D.A. Kristo, S.R. Bista, J.A. Rowley, R.S. Zak, K.R. Casey, C.I. Lamm, S.L. Tracy, R.S. Rosenberg, The treatment of restless legs syndrome and periodic limb movement disorder in adultsean update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline, Sleep 35 (8) (2012) 1039-1062.
63. A.S. Lim, E. Moro, A.M. Lozano, C. Hamani, J.O. Dostrovsky, W.D. Hutchison, A.E. Lang, R.A. Wennberg, B.J. Murray, Selective enhancement of rapid eye movement sleep by deep brain stimulation of the human pons, Ann. Neurol. 66 (1) (2009) 110-114.
64. J. Volkmann, A. Albanese, J. Kulisevsky, A.L. Tornqvist, J.L. Houeto, B. Pidoux, A.M. Bonnet, A. Mendes, A.L. Benabid, V. Fraix, N. Van Blercom, J. Xie, J. Obeso, M.C. Rodriguez-Oroz, J. Guridi, A. Schnitzler, L. Timmermann, A.A. Gironell, J. Molet, B. Pascual-Sedano, S. Rehncrona, E. Moro, A.C. Lang, A.M. Lozano, A.R. Bentivolgio, M. Scerrati, M.F. Contarino, L. Romito, M. Janssens, Y. Agid, Long-term effects of pallidal or subthalamic deep brain stimulation on quality of life in Parkinson's disease, Mov. Disord. 24 (8) (2009) 1154-1161.
65. P. Arias, J. Vivas, K.L. Grieve, J. Cudeiro, Double-blind, randomized, placebo controlled trial on the effect of 10 days low-frequency rTMS over the vertex on sleep in Parkinson's disease, Sleep. Med. 11 (8) (2010) 759-765.
66. N. Kovacs, F. Nagy, Z. Aschermann, E. Pal, High frequency repetitive transcranial magnetic stimulation of the motor cortex in Parkinson's disease: A randomized, double-blind, placebo-controlled study, Mov. Disord. 26 (Suppl. 2) (2011) S132eS133.
67. I. Leroi, P. Baker, P. Kehoe, E. Daniel, E.J. Byrne, A pilot randomized controlled trial of sleep therapy in Parkinson's disease: effect on patients and caregivers, Int. J. Geriatr. Psychiatry 25 (10) (2010) 1073-1079.
68. G.L. Willis, E.J.D. Turner, Primary and secondary features of Parkinson's disease improve with strategic exposure to bright light: a case series study, Chronobiol. Int. 24 (3) (2007) 521-537.
69. S. Paus, T. Schmitz-Hubsch, U. Wullner, A. Vogel, T. Klockgether, M. Abele, Bright light therapy in Parkinson's disease: a pilot study, Mov. Disord. 22 (10) (2007) 1495-1498.
70. Ö. Skogar, A. Borg, B. Larsson, L. Robertsson, L. Andersson, L. Andersson, P. Backstrom, P.-A. Fall, G. Hallgren, B. Bringer, M. Carlsson, U. Lennartsson, H. Sandbjork, J. Lokk, C.-J. Tornhage, "Effects of Tactile Touch on pain, sleep and health related quality of life in Parkinson's disease with chronic pain": A randomized, controlled and prospective study, Eur. J. Integr. Med. 5 (2) (2013) 141-152.
71. A.B. Neikrug, L. Liu, J.A. Avanzino, J.E. Maglione, L. Natarajan, L. Bradley, A. Maugeri, J. Corey-Bloom, B.W. Palmer, J.S. Loredo, S. Ancoli-Israel, Continuous positive airway pressure improves sleep and daytime sleepiness in patients with Parkinson disease and sleep apnea, Sleep 37 (1) (2014) 177-185.
72. N. Modugno, S. Iaconelli, M. Fiorlli, F. Lena, I. Kusch, G. Mirabella, Active theater as a complementary therapy for Parkinson's disease rehabilitation: a pilot study, Sci. World J. 10 (2010) 2301-2313.
73. C.L. Tomlinson, S. Patel, C. Meek, C.P. Herd, C.E. Clarke, R. Stowe, L. Shah, C. Sackley, K.H. Deane, K. Wheatley, N. Ives, Physiotherapy intervention in Parkinson's disease: systematic review and meta-analysis, BMJ 345 (2012) e5004.
74. B. Hogl, I. Arnulf, C. Comella, J.J. Ferreira, A. Iranzo, B. Tilley, C. Trenkwalder, W. Poewe, O. Rascol, C. Sampaio, G.T. Stebbins, A. Schrag, C.G. Goetz, Scales to assess sleep impairment in Parkinson's disease: critique and recommendations, Mov. Disord. 25 (16) (2010) 2704-2716.
75. K.F. Schulz, D.G. Altman, D. Moher, CONSORT, 2010 statement: updated guidelines for reporting parallel group randomised trials, BMJ 340 (2010) c332.